Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic...

Area of Science:

• Cardiology
• Medical Devices
• Clinical Trials

Background:

• Implantable cardioverter-defibrillators (ICDs) are used to prevent cardiac arrest in high-risk patients.
• Primary prevention strategies aim to mitigate risks before adverse events occur.

Purpose of the Study:

• To compare the efficacy of ICD therapy versus conventional care for primary prevention of mortality in adults with cardiomyopathy.
• To analyze outcomes in both ischemic and nonischemic cardiomyopathy patient groups.

Main Methods:

• A systematic review and meta-analysis of randomized controlled trials (RCTs) published between 1976 and 2017.
• Searched MEDLINE, Cochrane, Google Scholar, and EMBASE databases.
• Included 11 RCTs with 8716 patients, assessing all-cause and cause-specific mortality.

Main Results:

• ICD therapy reduced all-cause mortality by 27% (HR 0.81, P=0.043) compared to conventional care.
• Sudden cardiac death incidence decreased significantly from 12.15% to 4.39% with ICDs (HR 0.41).
• Mortality reductions were observed in both ischemic and nonischemic cardiomyopathy, though not all reached statistical significance.

Conclusions:

• Primary prevention with ICD therapy effectively reduces sudden and all-cause death in patients with cardiomyopathy.
• Heterogeneity in trial design, co-interventions, and patient populations were noted limitations.